Multiple novel series of
small molecule inhibitors of
DNA gyrase and topoisomerase IV, including a lead anti-MRSA molecule with in vivo efficacy and a favorable in vitro safety prof
ile. The technology of
fers potential options for Gram-positive pathogens (including MRSA, VRE, and Streptococcus pneumoniae), Gram-negative bacteria such as Neisseria gonorrhoeae and Acinetobacter baumannii, and mycobacteria (including Mycobacterium tuberculosis and non-tuberculous mycobacteria).
Antibiotic-resistant infections threaten large numbers of patients: the CDC conservatively estimates ~2 million such infections and 23,000 deaths annually in the United States alone. Globally, experts attributed 1.3 million deaths to resistant bacterial infections in 2019, with six pathogens accou…